ACADIA Pharmaceuticals Inc Approval Call Transcript - Thomson StreetEvents

ACADIA Pharmaceuticals Inc Approval Call Transcript

ACADIA Pharmaceuticals Inc Approval Call Transcript - Thomson StreetEvents
ACADIA Pharmaceuticals Inc Approval Call Transcript
Published Mar 13, 2023
22 pages (12805 words) — Published Mar 13, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ACAD.OQ corporate analyst meeting

  
Brief Excerpt:

...Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals DAYBUE FDA Approval Call. My name is Michelle, and I will be your coordinator for today. (Operator Instructions) I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please go ahead. Mark C. Johnson ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
ACADIA Pharmaceuticals Inc
Ticker
ACAD.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Great. Let me add my congratulations on the approval as well. Steve, maybe just a quick 1 for me. At the top of the call, you commented on the Stoke collaboration specifically. I'm just curious how you're building trust and establishing success in the Rett community is key to your positioning of that program as well as any other R&D efforts as you prioritize not just this community with DAYBUE, but also with additional treatment options in development.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : It's nice to see an approved option for patients with it. What's the current fraction of Rett patients who might be dosed by (inaudible)? And how do you expect that traction to change given the availability of DAYBUE. And then just on the priority review, how would you define value if you were to use the priority review (inaudible) for your side?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : I mean, sorry, a clarification, what if you use it for yourself rather than monetize it? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 13, 2023 / 12:30PM, ACAD.OQ - ACADIA Pharmaceuticals Inc Approval Call

Table Of Contents

ACADIA Pharmaceuticals Inc Q2 2023 Earnings Call Transcript – 2023-08-02 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 2-Aug-23 8:30pm GMT

ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript – 2023-07-13 – US$ 54.00 – Edited Transcript of ACAD.OQ conference call or presentation 13-Jul-23 8:30pm GMT

ACADIA Pharmaceuticals Inc to Announce Phase 3 Development Candidate ACP-101 Call Transcript – 2023-06-13 – US$ 54.00 – Edited Transcript of ACAD.OQ conference call or presentation 13-Jun-23 9:00pm GMT

ACADIA Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript – 2023-05-10 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 10-May-23 6:20pm GMT

ACADIA Pharmaceuticals Inc Q1 2023 Earnings Call Transcript – 2023-05-08 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 8-May-23 8:30pm GMT

ACADIA Pharmaceuticals Inc Q4 2022 Earnings Call Transcript – 2023-02-27 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 27-Feb-23 9:30pm GMT

ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript – 2023-01-10 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 10-Jan-23 5:00pm GMT

ACADIA Pharmaceuticals Inc Q3 2022 Earnings Call Transcript – 2022-11-02 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 2-Nov-22 8:30pm GMT

ACADIA Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript – 2022-09-13 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 13-Sep-22 3:10pm GMT

ACADIA Pharmaceuticals Inc at Citi BioPharma Conference Transcript – 2022-09-08 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 8-Sep-22 5:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "ACADIA Pharmaceuticals Inc Approval Call Transcript" Mar 13, 2023. Alacra Store. May 12, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/ACADIA-Pharmaceuticals-Inc-Approval-Call-T15512514>
  
APA:
Thomson StreetEvents. (2023). ACADIA Pharmaceuticals Inc Approval Call Transcript Mar 13, 2023. New York, NY: Alacra Store. Retrieved May 12, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/ACADIA-Pharmaceuticals-Inc-Approval-Call-T15512514>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.